Evogene - Stock Price History | EVGN

Historical daily share price chart and data for Evogene since 2021 adjusted for splits. The latest closing stock price for Evogene as of September 27, 2021 is 2.85.
  • The all-time high Evogene stock closing price was 19.99 on December 12, 2013.
  • The Evogene 52-week high stock price is 10.24, which is 259.3% above the current share price.
  • The Evogene 52-week low stock price is 2.38, which is 16.5% below the current share price.
  • The average Evogene stock price for the last 52 weeks is 4.13.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Evogene Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.9523 1.6700 5.6300 0.7500 4.7000 209.21%
2019 1.7603 2.2000 2.4700 1.2850 1.5200 -23.23%
2018 3.0482 3.4700 4.1600 1.9800 1.9800 -35.50%
2017 4.7684 5.0800 5.5500 3.0700 3.0700 -39.80%
2016 6.5320 8.1401 8.4200 5.1000 5.1000 -36.65%
2015 8.7703 9.2200 10.4150 6.5000 8.0500 -12.60%
2014 15.0789 19.2314 19.9100 8.7400 9.2100 -53.13%
2013 12.6537 9.4000 19.9900 9.4000 19.6500 109.04%
2012 8.4478 8.2000 9.5600 7.0400 9.4000 14.63%
2011 9.4778 11.2000 11.3400 7.9000 8.2000 -26.79%
2010 10.0267 9.6200 11.4400 9.6200 11.2000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.001B
Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29